{"nctId":"NCT02311907","briefTitle":"Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer","startDateStruct":{"date":"2009-12"},"conditions":["Chemotherapeutic Agent Toxicity","Neuropathy","Neurotoxicity Syndrome","Pain","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer"],"count":195,"armGroups":[{"label":"Arm I (glutathione, carboplatin)","type":"EXPERIMENTAL","interventionNames":["Drug: Carboplatin","Drug: Glutathione","Other: Laboratory Biomarker Analysis","Drug: Paclitaxel","Other: Quality-of-Life Assessment"]},{"label":"Arm II (placebo, paclitaxel)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Carboplatin","Other: Laboratory Biomarker Analysis","Drug: Paclitaxel","Other: Placebo","Other: Quality-of-Life Assessment"]}],"interventions":[{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplat","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"]},{"name":"Glutathione","otherNames":["Glutham","GSH","Reduced Glutathione"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"]},{"name":"Placebo","otherNames":["placebo therapy","PLCB","sham therapy"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Scheduled to undergo treatment with TAXOL at 150-200 mg/m2 and CBDCA at area under the curve (AUC) = 5-7 every 21 or 28 days for at least 12 weeks; alternatively, paclitaxel can be prescribed at 80 mg/m2 weekly for at least 12 weeks, with the same CBDCA dose of AUC = 5-7 every 21 days; additional chemotherapy agents are allowed (bevacizumab, etoposide, etc) per physician discretion, as long as they are not known to be neurotoxic; Note: patients ideally will begin GSH therapy prior to their first dose of this chemotherapy, but must begin GSH therapy prior to their second dose of chemotherapy\n* Ability to sign informed consent and understand the nature of a placebo-controlled trial\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Ability to complete English language questionnaire(s) by themselves or with assistance\n* Life expectancy \\>= 6 months\n* Negative pregnancy test done =\\< 7 days prior to registration, for women of childbearing potential only, per clinician discretion\n* Willingness to provide blood specimens as required by the protocol\n* White blood cell (WBC) \\>= 3400\n* Absolute neutrophil count (ANC) \\>= 1500\n* Platelet (PLT) \\>= 100,000\n* Hemoglobin (HgB) \\> 10.0\n* Creatinine =\\< 1.5 x upper limit of normal (ULN)\n\nExclusion Criteria:\n\n* Pre-existing history of peripheral neuropathy \\> grade 1 (National Cancer Institute \\[NCI\\] CTCAE version \\[v\\] 4.0) due to any cause (e.g., chemotherapy, diabetes, alcohol, toxin, or heredity)\n* Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Women of childbearing potential who are unwilling to employ adequate contraception\n* Prior TAXOL and/or CBDCA chemotherapy treatment (other than the current treatment regimen)\n* Concurrent use of any agent being used specifically to prevent or treat neuropathy, including but not limited to the following:\n\n  * Gabapentin\n  * Glutamine powder or glutamine tablets\n  * Vitamin B6 or E","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).","description":"The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale (higher scores indicated less symptoms and better quality of life). Generalized linear models (repeated measures analysis of variance \\[ANOVA\\] if data are complete) will be used to compare the CIPN between Glutathione (GSH) and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":"0.89"},{"groupId":"OG001","value":"82.1","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Recurrence-free Survival (for Patients Without Clinical Evidence of Disease)","description":"A log-rank test and a Kaplan-Meier curve will be used to compare the recurrence free survival between GSH and placebo arms (for ovarian/fallopian tube/primary peritoneal patients only).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Patient Reported Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and Patient Daily-symptom Questionnaires Over Time.","description":"Quality of life was measured by FACT-O (on a 0 to 100 scale, higher scores represent better life quality) from baseline and at the end of TAXOL/CBDCA. The change in Quality of Life was calculated as the difference between baseline measure and end of treatment measure (with range from -100 to 100). A negative change represents a worsening in QOL from baseline to one year. Abbreviations used: Change from Baseline (chg from bsl)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":null},{"groupId":"OG001","value":"-8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Paclitaxel Acute Pain Syndrome Incidence and Severity Between GSH and Placebo Arms","description":"Descriptive statistics will be used to describe TAXOL/CBDCA acute pain syndrome incidence/severity between GSH and placebo arms. Pain was scored on a scale from 0-10, where 0 = 'No aches or pains' and 10 = 'Aches or pains as bad as can be.'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Delaying PC Chemotherapy Secondary to PN","description":"Patients delaying TAXOL/CBDCA secondary to peripheral neuropathy between GSH and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Undergoing Dose Reductions Secondary to PCI PN","description":"Proportion of patients requiring chemotherapy dose reductions secondary to TAXOL/CBDCA induced peripheral neuropathy between GSH and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Grade 2+ and Grade 3+ Paclitaxel/Carboplatin-induced (PCI) Peripheral Neuropathy (PN) According to the Common Terminology Criteria for Adverse Events (CTCAE) Neuropathy Scale","description":"Proportion of grade 2+ and grade 3+ chemotherapy induced peripheral neuropathy (CIPN) at any time during or at the end of the TAXOL/CBDCA based chemotherapy between GSH and placebo arms. Neuropathy scale has grades 1 through 5 (1-mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening and Grade 5 Death related to AE).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":null},{"groupId":"OG001","value":"33.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Times to Onset of CTCAE Grade 2+ PN","description":"Compare time to grade 2+ CIPN between GSH and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"18.5"},{"groupId":"OG001","value":"234","spread":"26.1"}]}]}]},{"type":"SECONDARY","title":"Times to Onset of CTCAE Grade 3+ PN","description":"Time to grade 3+ CIPN between GSH and placebo arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":94},"commonTop":["Neutrophil count decreased","Anemia","Fatigue","Peripheral sensory neuropathy","White blood cell decreased"]}}}